Coya Therapeutics hits its 100th ALS trial enrollment and publishes new preclinical data, both pointing to the same ...

Inside the $230 billion our new Longevity Biotech Report says the pipeline is already worth – no regulatory rewrite required.

Telomir’s oncology compound helped fish with age-related retinal damage see better and moved two aging-linked markers toward ...

Enveda raised $311 million to push its AI-discovered medicines forward, including one aimed at life after GLP-1 drugs.

Phil Newman analyzes Oura’s IPO and lawsuit, movement context in dementia, GenFlow dog trial, Rentosertib aging clocks, and ...

A new connector lets Function Health members bring lab results and biomarker trends straight into Meta’s personal AI agent, ...

A new PowerPlug puts a person’s medical history beside their Ring readings and flags follow-ups that may have slipped through. The average doctor’s appointment in the US lasts 15 minutes, according to ...

Belgian clinical data show Allegro’s nanotech injection Hydrocelin delivers lasting knee osteoarthritis relief from a single ...

Alzheon’s peer-reviewed data tie a falling blood marker to slower memory and brain decline in patients taking its daily pill.

Seoul biotech’s redesigned method makes circular RNA up to seven times more efficient to build, widening what RNA medicine can treat.

NKGen presented new clinical data on troculeucel’s potential in Alzheimer’s, Parkinson’s and frontotemporal dementia.

Longevity brand launches a spray tech that skips gut entirely, betting that how a supplement is delivered matters as much as what’s in it. Swallow a supplement, and it’s got a rough trip ahead.